🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT07456332
Enrolling by invitation Not applicable

Effect on Body Weight Reduction of a Behavioral Intervention on Lifestyle Using a Digital Nutritional Program in People Living With HIV and Metabolic Dysfunction-associated Steatotic Liver Disease

NCT07456332 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2025-04-23
Last updated
2026-03-10

Condition(s) studied

Metabolic Dysfunction-Associated Steatotic Liver DiseasePeople Living With HIVLife Style

Investigational drug(s) / intervention(s)

Digital nutritional programStandard care dietary and exercice advice.

Digital nutritional program: * Web registration and download of the aplication: After signing the informed consent, the investigator will pre-register the participant on a page provided for this purpose. The patient will then receive an email with instructions to registre and download the digital nutritional program The user's pasword will be stored encrypted. Once received, the participant must fill out the start form. This form has the mission of conducting the dietitian-nutritionist on eating habits and lifestyles and to guide nutritional intervention. * Digital nutritional program: apply cognitive-behavioural techniques to promote healthy eating for each participant and ensure their understanding of the most important aspects for their Health, regarding their chronic conditions and the treatments they are undergoing. DNP will offer a program that tailors meal plans to patients' specific pathologies and circumstances via a mobile application.

Standard care dietary and exercice advice.: Advice on healthy lifestyle recommendations given by a trained physician or nurse, based on a Mediterranean diet (based on fruits, vegetables, legumes, whole grains, fish or white meat and olive oil; avoid processed foods, red meat and sugary drinks). Delivery of written resources containing healthy eating guidelines and advice.

Study summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease in people living with HIV (PLWH). Currently, there are no approved medications to treat this condition. That's why weight loss through healthy lifestyle changes is the most important way to manage it.

This study will test if a digital nutritional program (DNP), using a mobile phone app, can help improve weight loss better than the usual advice on healthy eating and exercise.

The study includes people living with HIV, aged 18 and older, with fatty liver (detected by ultrasound or other scans), and on stable HIV treatment.

Participants will be randomly assigned to two groups:

* Intervention group: Will receive personalized lifestyle support through a mobile app (DNP).
* Control group: Will receive general advice on healthy habits. The study will last 12 months, with follow-up visits during and after the program.

What Will Be Measured:

* Weight, waist size, blood pressure, and body fat.
* Blood tests to check cholesterol, sugar levels, liver enzymes, and other markers.
* Liver scans to assess fat and stiffness.
* Questionnaires on eating habits, exercise, and satisfaction with the program.

Goals of the Study:

Main goal: To see how many people lose at least 5% of their body weight after 6 months.

Other goals: To see the effects on weight after 12 months, and 6 months after stopping the program, and to monitor improvements in liver health.

Why This Matters:

This study aims to find new ways to help people with HIV improve their liver health and overall well-being through simple, practical tools like a mobile app.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * HIV-infected patients * ≥ 18 years of age * On stable antiretroviral therapy during the last 6 months * HIV viral load \<50 copies/ml for ≥ 6 months * CD4 cell count \>200 cells/uL * Diagnosis of liver steatosis on ultrasound or Controlled Attenuation Parameter (CAP) measured by vibration-controlled transient elastography Exclusion Criteria: * Body mass index ≤ 23 kg/m2 * Presence of a condition that precluded modification of activity or diet behaviour * Known liver disease other tan MASLD including viral, haemochromatosis, Wilson's Disease, alpha-1 antitripsin deficiency, autoimmune hepatitis and cirrhosis * Excessive alcohol consumption (\>15 gr/day for women and 30 gr/day for men), * Endocrine disorders: hyperthyroidism or uncontrolled hypothyroidism * Pharmacological treatment with immunosuppressants, cytotoxic agents, systemic corticosteroids, or other drugs that could potentially cause hepatic steatosis (amiodarone, tamoxifen, methotrexate) or alter liver tests * The use of weight modifiers or previous weight loss surgery at any time * Cardiovascular event in the last 6 months * Stage 4 and above kidney disease * Active infection, cancer or autoimmune disease * Inability to use an internet application or not having a Smartphone, * Low command of spanish or illiteracy, * Refusal to give informed consent * Pregnant women or women planning pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelona

More Hospital Universitari de Bellvitge trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07456332 on ClinicalTrials.gov ↗ ← All trials in Spain